UFP Technologies (UFPT) has drawn fresh attention after its recent share price move, with the stock closing at US$258.68. Investors are weighing that level against the company’s longer term return profile.

That soft 1 day share price return of 2.99% and 7 day share price return of 0.71% comes after a stronger run, with a 30 day share price return of 9.05% and a 90 day share price return of 29.33%. The 3 year total shareholder return of about 2.4x and 5 year total shareholder return of about 5.6x point to a long running, if sometimes volatile, story where recent momentum is still building.

If UFP Technologies has caught your eye, this could be a good moment to broaden your watchlist and check out other healthcare stocks that might fit a similar thesis.

So with the shares sitting around US$258.68, a value score of 1, analyst targets closer to US$329.50, and recent total returns mixed across timeframes, the key question is whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 21.5% Undervalued

With UFP Technologies last closing at $258.68 against a narrative fair value of $329.50, the current setup centers on whether earnings and margins can evolve to support that higher price over time.

The expansion of manufacturing capacity and product development centers in the Dominican Republic, along with new program launches for robotic-assisted surgery customers, sets the stage for sustained revenue growth tied to increased demand for sophisticated medical device components and packaging solutions.

Want to see what is baked into that higher value? Revenue trends, margin lift and a richer earnings multiple all sit at the core of this narrative. Curious which assumptions really move the needle on that target number?

Result: Fair Value of $329.50 (UNDERVALUED)

However, concentration in a few large medical customers, along with potential hiccups integrating recent acquisitions, could easily knock this upbeat story off course.

Another View: Richer Pricing On Earnings

The narrative fair value of $329.50 paints UFP Technologies as undervalued, but the current P/E of 29.7x tells a tighter story. It sits below the US Medical Equipment industry average of 32x, yet well above a fair ratio of 20.6x and a peer average of 23.4x. This points to a valuation that already appears to incorporate a significant degree of optimism. The question is whether you think the business can keep justifying that premium.

Build Your Own UFP Technologies Narrative

If you see the numbers differently or prefer to walk through the data yourself, you can shape your own view in just a few minutes by starting with Do it your way.

A great starting point for your UFP Technologies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one company, you could easily miss other opportunities that fit your style, so take a few minutes to widen your search with targeted screeners.

• Spot potential turnaround candidates by checking out these 3523 penny stocks with strong financials that pair smaller share prices with stronger underlying financials.
• Focus on the intersection of medicine and algorithms by scanning these 109 healthcare AI stocks that may be shaping the next wave of care and diagnostics.
• Build your watchlist around value-driven choices by reviewing these 874 undervalued stocks based on cash flows that compare prices with underlying cash flow characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.